BiBB receives an Intention to Grant for EndoDrill patent in Europe
The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the European Patent Office (EPO). The notice means that the EPO intends to approve a divisional patent application (first patent family) in Europe for EndoDrill®. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.
BIBB has received an Intention to Grant from the EPO regarding the approval of the patent application EP23176928.2, which concerns a divisional patent application for specific protection of the EndoDrill® technology. The claims in this patent application closely reflect the commercial EndoDrill® instruments in the product portfolio. Since September 2023, BiBB has had two approved patents in Europe with slightly different scopes. The Company has three international patent applications for EndoDrill® that have entered the national/regional phase, with patents approved so far in Europe, Japan and India. Other patent applications will be pursued toward approval to provide global protection for the market's first electric-driven endoscopic biopsy instrument.
”A very important and well-timed advance notice for us regarding another patent approval in Europe. With both CE marking and a strong patent position behind us, we have a valuable head start in the commercialization of our EndoDrill® product portfolio in Europe," says Fredrik Lindblad, CEO of BiBB.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: [email protected]
Phone: +46 70 899 94 86
www.bibbinstruments.com
This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 4, 2024.
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill® GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. Thus EndoDrill® is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill® system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.